Brief Communication | Published:

Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen

Nature Structural & Molecular Biology volume 12, pages 822823 (2005) | Download Citation


This article has been updated


Human microsomal cytochrome P450 2A6 (CYP2A6) contributes extensively to nicotine detoxication but also activates tobacco-specific procarcinogens to mutagenic products. The CYP2A6 structure shows a compact, hydrophobic active site with one hydrogen bond donor, Asn297, that orients coumarin for regioselective oxidation. The inhibitor methoxsalen effectively fills the active site cavity without substantially perturbing the structure. The structure should aid the design of inhibitors to reduce smoking and tobacco-related cancers.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 14 August 2005

    Sentence changed



  1. 1.

    , & Clin. Pharmacol. Ther. 77, 145–158 (2005).

  2. 2.

    , & Clin. Pharmacol. Ther. 68, 35–43 (2000).

  3. 3.

    , , , & Nicotine Tob. Res. 5, 891–899 (2003).

  4. 4.

    et al. Carcinogenesis 18, 1623–1630 (1997).

  5. 5.

    & Environ. Mol. Mutagen. 38, 339–346 (2001).

  6. 6.

    in Cytochrome P450: Structure, Mechanism, and Biochemistry (ed. Ortiz de Montellano, P.R.) 377–530 (Kluwer Academic/Plenum Publishers, New York, 2005).

  7. 7.

    Drug Metab. Dispos. 31, 1532–1540 (2003).

  8. 8.

    & Science 229, 23–28 (1985).

  9. 9.

    & J. Am. Chem. Soc. 125, 7413–7424 (2003).

  10. 10.

    , , & J. Biol. Chem. 280, 12279–12291 (2005).

  11. 11.

    & Biochemistry 37, 10047–10061 (1998).

  12. 12.

    & Acta Crystallogr. D 50, 178–185 (1994).

Download references


This work was supported by the US National Institutes of Health grant GM031001 (to E.F.J.) and fellowship 12FT-0185 from the Tobacco-Related Disease Research Program (to J.K.Y.). Facilities for computer-assisted sequence analysis, DNA sequencing and the synthesis of oligonucleotides were supported in part by the General Clinical Research Center grant M01 RR00833 and by the Sam and Rose Stein Charitable Trust. Portions of this research were carried out at the Stanford Synchrotron Radiation Laboratory (SSRL), a national user facility operated by Stanford University on behalf of the US Department of Energy, Office of Basic Energy Sciences. The SSRL Structural Molecular Biology Program is supported by the Department of Energy, Office of Biological and Environmental Research and by the US National Institutes of Health, National Center for Research Resources, Biomedical Technology Program and National Institute of General Medical Sciences. The authors thank F. Gonzalez (National Cancer Institute) for kindly providing the CYP2A6 cDNA.

Author information


  1. Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037, USA.

    • Jason K Yano
    • , Mei-Hui Hsu
    • , Keith J Griffin
    •  & Eric F Johnson
  2. Department of Molecular Biology, Scripps Research Institute, La Jolla, California 92037, USA.

    • C David Stout


  1. Search for Jason K Yano in:

  2. Search for Mei-Hui Hsu in:

  3. Search for Keith J Griffin in:

  4. Search for C David Stout in:

  5. Search for Eric F Johnson in:

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to C David Stout or Eric F Johnson.

Supplementary information

PDF files

  1. 1.

    Supplementary Fig. 1

    The overall fold of CYP2A6 and comparison with CYP2C8.

  2. 2.

    Supplementary Fig. 2

    Residue interactions that contribute to a compact polypeptide fold.

  3. 3.

    Supplementary Fig. 3

    Wall-eyed stereo view of the potential hydrogen bonding of Asn297.

  4. 4.

    Supplementary Table 1

    Data collection and refinement statistics.

  5. 5.

    Supplementary Methods

About this article

Publication history





Further reading